πŸ“£ VC round data is live. Check it out!

KalVista Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for KalVista Pharmaceuticals and similar public comparables like Youcare Pharmaceutical, Harrow, HBM Holdings, UroGen Pharma and more.

KalVista Pharmaceuticals Overview

About KalVista Pharmaceuticals

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.


Founded

2004

HQ

United States

Employees

270

Financials (LTM)

Revenue: $105M
Net Income: ($88M)

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

KalVista Pharmaceuticals Financials

KalVista Pharmaceuticals reported last 12-month revenue of $105M.

In the same LTM period, KalVista Pharmaceuticals generated $96M in gross profit and had net loss of ($88M).

Revenue (LTM)


KalVista Pharmaceuticals P&L

In the most recent fiscal year, KalVista Pharmaceuticals reported revenue of $49M and EBITDA of ($173M).

KalVista Pharmaceuticals is unprofitable as of last fiscal year, with EBITDA margin of (353%) and net margin of (223%).

See analyst estimates for KalVista Pharmaceuticals
LTMLast FY202320242025202620272028
Revenue$105M$49Mβ€”β€”$138M
Gross Profit$96Mβ€”β€”($3M)$123M
Gross Margin91%β€”β€”β€”89%
EBITDAβ€”($173M)($124M)($159M)($103M)
EBITDA Marginβ€”(353%)β€”β€”(75%)
EBIT Margin(86%)(228%)β€”β€”(68%)
Net Profit($88M)($110M)($115M)($165M)($93M)
Net Margin(83%)(223%)β€”β€”(67%)

Financial data powered by Morningstar, Inc.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


KalVista Pharmaceuticals' stock price is $26.73.

KalVista Pharmaceuticals share price increased by 0.3% in the last 30 days, and by 126.5% in the last year.

KalVista Pharmaceuticals has an EPS (earnings per share) of $-2.06.

See more trading valuation data for KalVista Pharmaceuticals
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B0.0%0.3%64.2%126.5%$-2.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

KalVista Pharmaceuticals Valuation Multiples

KalVista Pharmaceuticals trades at 12.1x EV/Revenue multiple, and (7.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for KalVista Pharmaceuticals

EV / Revenue (LTM)


KalVista Pharmaceuticals Financial Valuation Multiples

As of May 9, 2026, KalVista Pharmaceuticals has market cap of $1B and EV of $1B.

KalVista Pharmaceuticals has a P/E ratio of (16.2x).

LTMLast FY202320242025202620272028
EV/Revenue12.1x25.9xβ€”β€”9.2x
EV/EBITDAβ€”(7.3x)(10.2x)(8.0x)(12.3x)
EV/EBIT(14.1x)(11.4x)(10.2x)(7.7x)(13.5x)
EV/Gross Profit13.3xβ€”β€”n/m10.3x
P/E(16.2x)(13.0x)(12.3x)(8.6x)(15.3x)
EV/FCFβ€”(8.3x)(14.9x)(9.6x)(8.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified KalVista Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

KalVista Pharmaceuticals Margins & Growth Rates

KalVista Pharmaceuticals grew revenue by 323% but EBITDA decreased by 61% in the last fiscal year.

In the most recent fiscal year, KalVista Pharmaceuticals reported EBITDA margin of (353%) and net margin of (223%).

See estimated margins and future growth rates for KalVista Pharmaceuticals

KalVista Pharmaceuticals Margins

Last FY20252026202720282029
Gross Marginβ€”89%91%
EBITDA Margin(353%)(75%)(4%)
EBIT Margin(228%)(68%)3%
Net Margin(223%)(67%)3%
FCF Margin(313%)(111%)β€”

KalVista Pharmaceuticals Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth323%β€”β€”98%
Gross Profit Growthβ€”β€”(4082%)103%
EBITDA Growth(61%)28%(35%)(90%)
EBIT Growth(56%)33%(43%)(108%)
Net Profit Growth(56%)43%(43%)(108%)
FCF Growthβ€”55%16%β€”

Data powered by FactSet, Inc. and Morningstar, Inc.

KalVista Pharmaceuticals Operational KPIs

KalVista Pharmaceuticals' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.7M for the same period.

KalVista Pharmaceuticals' Rule of 40 is 95% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

KalVista Pharmaceuticals' Rule of X is 242% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for KalVista Pharmaceuticals
LTMLast FY2025202620272028
Rule of 40β€”95%β€”
Bessemer Rule of Xβ€”242%β€”
Revenue per Employeeβ€”$0.2Mβ€”
Opex per Employeeβ€”$0.7Mβ€”
G&A Expenses to Revenue139%254%118%
R&D Expenses to Revenue34%146%37%
Opex to Revenueβ€”373%132%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

KalVista Pharmaceuticals Competitors

KalVista Pharmaceuticals competitors include Youcare Pharmaceutical, Harrow, HBM Holdings, UroGen Pharma, Maze Therapeutics, Jiangxi Fushine Pharma, Liaoning Chengda Biotech, Semnur Pharmaceuticals, Eczacıbaşı İlaç and WAVE Life Sciences.

Most KalVista Pharmaceuticals public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Youcare Pharmaceutical3.6xβ€”(1236.5x)β€”
Harrow5.9x5.3x25.9x23.1x
HBM Holdings6.9x6.0x11.1x10.8x
UroGen Pharma13.5x9.1x(11.9x)(17.3x)
Maze Therapeuticsβ€”253.4x(8.0x)(7.7x)
Jiangxi Fushine Pharma8.9x6.8x65.5x23.8x
Liaoning Chengda Biotech3.5x3.6x13.8x15.7x
Semnur Pharmaceuticalsβ€”β€”(8.7x)β€”

This data is available for Pro users. Sign up to see all KalVista Pharmaceuticals competitors and their valuation data.

Start Free Trial

KalVista Pharmaceuticals Funding History

Before going public, KalVista Pharmaceuticals raised $33M in total equity funding, across 1 round.


KalVista Pharmaceuticals Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-15Series BLongwood Fund; Novo Holdings; RA Capital Management; SV Health Investors; Venrock$33Mβ€”KalVista Pharmaceuticals announced a Series B financing round raising $33 million to advance development of its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). The round was led by RA Capital Management and included participation from existing investors Novo A/S and SV Life Sciences, along with new investors Longwood Fund and Venrock. Rajeev Shah from RA Capital and Rich Aldrich from Longwood Fund joined KalVista's Board of Directors, while Bong Koh from Venrock and Tomas Kiselak from RA Capital joined as Board observers. CEO Andrew Crockett stated that the financing would allow the company to rapidly advance its programs toward clinical proof-of-concept milestones and bring treatments to patients with serious diseases. The syndicate brought considerable experience in plasma kallikrein-targeted mechanisms and small molecule drug development.

KalVista Pharmaceuticals M&A Activity

KalVista Pharmaceuticals has acquired 1 company to date.

Last acquisition by KalVista Pharmaceuticals was on June 15th 2016. KalVista Pharmaceuticals acquired Carbylan Therapeutics for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by KalVista Pharmaceuticals

Carbylan Therapeutics
Description
Carbylan Therapeutics is a Palo Alto-headquartered clinical-stage biopharmaceutical company developing combination therapies for underserved markets. Founded in 2004, it advances proprietary formulations targeting pain management and gastrointestinal disorders through late-stage trials in the United States.
HQ CountryUnited States
HQ City
San Francisco, CA
Deal Date15 Jun 2016
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all KalVista Pharmaceuticals acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About KalVista Pharmaceuticals

When was KalVista Pharmaceuticals founded?KalVista Pharmaceuticals was founded in 2004.
Where is KalVista Pharmaceuticals headquartered?KalVista Pharmaceuticals is headquartered in United States.
How many employees does KalVista Pharmaceuticals have?As of today, KalVista Pharmaceuticals has over 270 employees.
Who is the CEO of KalVista Pharmaceuticals?KalVista Pharmaceuticals' CEO is Benjamin L. Palleiko.
Is KalVista Pharmaceuticals publicly listed?Yes, KalVista Pharmaceuticals is a public company listed on Nasdaq.
What is the stock symbol of KalVista Pharmaceuticals?KalVista Pharmaceuticals trades under KALV ticker.
When did KalVista Pharmaceuticals go public?KalVista Pharmaceuticals went public in 2015.
Who are competitors of KalVista Pharmaceuticals?KalVista Pharmaceuticals main competitors include Youcare Pharmaceutical, Harrow, HBM Holdings, UroGen Pharma, Maze Therapeutics, Jiangxi Fushine Pharma, Liaoning Chengda Biotech, Semnur Pharmaceuticals, Eczacıbaşı İlaç, WAVE Life Sciences.
What is the current market cap of KalVista Pharmaceuticals?KalVista Pharmaceuticals' current market cap is $1B.
What is the current revenue of KalVista Pharmaceuticals?KalVista Pharmaceuticals' last 12 months revenue is $105M.
What is the current revenue growth of KalVista Pharmaceuticals?KalVista Pharmaceuticals revenue growth (NTM/LTM) is 131%.
What is the current EV/Revenue multiple of KalVista Pharmaceuticals?Current revenue multiple of KalVista Pharmaceuticals is 12.1x.
Is KalVista Pharmaceuticals profitable?No, KalVista Pharmaceuticals is not profitable.
What is the current net income of KalVista Pharmaceuticals?KalVista Pharmaceuticals' last 12 months net income is ($88M).
How many companies KalVista Pharmaceuticals has acquired to date?As of May 2026, KalVista Pharmaceuticals has acquired 1 company.
What was the largest acquisition by KalVista Pharmaceuticals?None of the M&A deals KalVista Pharmaceuticals has completed have disclosed valuations.
What companies KalVista Pharmaceuticals acquired?KalVista Pharmaceuticals acquired Carbylan Therapeutics.
In how many companies KalVista Pharmaceuticals has invested to date?KalVista Pharmaceuticals hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to KalVista Pharmaceuticals

Lists including KalVista Pharmaceuticals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial